ICON's cardiovascular trial experience, supported by a global team of experts

A multifaceted risk factor: Addressing obesity's impact across the disease spectrum

With obesity as a risk factor across the disease spectrum, there are several unique considerations and strategies for sponsors and researchers to account for in their approach to development and clinical trials for obesity treatment.

Read the whitepaper

From genomics to the coming of age glycomics

Discover how glycan biomarkers are quickly becoming key elements of cancer, cardiovascular, and gastrointestinal research, setting the stage for a new golden age of epigenetic research and personalised therapeutics.

Read the whitepaper

Mitigating the impact of COVID-19 on cardiovascular trials

COVID-19 has had a significant impact on the conduct of clinical trials and participants. Participants in cardiovascular (CV) trials typically are older, with underlying CV disease or risk factors such as hypertension and diabetes – a population at higher risk of death from COVID-19 if they contract the virus. As a result, these individuals may have heightened concerns about participating in a clinical trial due to the potential for exposure to COVID-19. Discover measures that can be implemented in ongoing trials to ensure the safety of participants, maximise retention and maintain trial integrity

Read the whitepaper

Thriving in Value-Based Healthcare: A guide for cardiovascular medical device manufacturers

In December 2016, the Centers for Medicare & Medicaid Services (CMS) expanded the Bundled Payments for Care Improvement (BPCI) Initiative to include cardiovascular and hip fracture services, taking a major step in the march towards value-based care in the US. Read how can medical device manufacturers sustain growth and successfully navigate this new model?

Download the whitepaper

Reimagining patient-centric clinical trials with the IoMT

Follow a theoretical patient through the entire clinical trial journey – from initial contact for an early study through transition to treatment with an approved product. At each stage, we explore how IoMT can increase clinical development programme efficiency by reducing the burden on patients, caregivers, pharma companies and medical device and diagnostic manufacturers.

Download the whitepaper

Cardiovascular event adjudication during COVID-19 and beyond

In this webinar you will learn more about best practices for cardiovascular event adjudication across drug and device trials, including recent advances in the selection and application of connected devices.

Access the webinar recording

Latest on Cardiovascular, Metabolic, and Circulation

If you would like to receive our Cardiovascular email updates, including the latest on cardiovascular clinical trials, click here to go to our preference centre

Receive Cardiovascular email updates

Blogs and media articles relating to cardiovascular and metabolic clinical trials

Cardiovascular clinical trials services at ICON

ICON has over 25 years' experience conducting cardiovascular trials, with particular emphasis on key cardiovascular/metabolic indications: heart failure, lipid disorders, diabetes, renal insufficiency and renal transplant, arrhythmia, and rare diseases.

Read more about ICON's Cardiovascular clinical trials services